Neurocrine Biosciences | Capitaux D'Emprunt



Loan Capital Changement Date
AbbVie USD 64.53B 4.19B 2025-03
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 0 0 2025-03
Alnylam Pharmaceuticals USD 1.03B 956K 2025-06
Amgen USD 53.76B 253M 2025-06
Biogen USD 6.28B 1.74B 2025-06
BioMarin Pharmaceutical USD 596.16M 512K 2025-06
Cytokinetics USD 713.04M 67.88M 2025-06
Dynavax Technologies USD 220.75M 39.75M 2025-06
Exelixis USD 0 0 2025-04
Gilead Sciences USD 22.14B 6M 2025-06
Halozyme Therapeutics USD 1.51B 1.65M 2025-06
Incyte USD 31.76M 883K 2025-06
Ionis Pharmaceuticals USD 625.49M 625.22M 2025-06
Neurocrine Biosciences USD 0 0 2024-12
Pfizer USD 57.5B 137M 2025-06
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 1.99B 719.7M 2025-06
Repligen USD 533.72M 4.12M 2025-06
Sarepta Therapeutics USD 1.14B 1.17M 2025-06
Teva Pharmaceutical Industries USD 16.76B 533M 2025-06
Ultragenyx Pharmaceutical USD 782.75M 782.75M 2025-06
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12


Neurocrine Biosciences Capitaux D'Emprunt - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.